本帖最后由 老马 于 2012-1-13 21:20 编辑 9 |3 A# E2 @8 i! `4 x& t; @
1 F1 q% h1 j' g7 B1 D& f爱必妥和阿瓦斯丁的比较
+ Q* a4 _& [) @5 C& f
" k* x- x' p1 Bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 e, ]" ^% |( T2 w% ?
# m) L! L1 @% K9 B1 a
% x* `+ P1 M1 r( H% \5 {
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* d( M* I; x X% h* S; [/ C n
==================================================
. T5 D7 }9 Z8 @* S$ _5 K+ WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 [+ e; a( W, e$ }9 P2 Y2 [5 L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 `& N% W4 ~" |Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: D# I5 F$ q l: ~1 D) e7 J3 q
|